RxDoctor Payments Data

Gerard Eichman, MD

Cardiovascular Disease · Teaneck, NJNPI 1699774950

Payments from drug & device makers

$15,871in general payments, 2019–2025

Across 668 payments — averaging $23.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Johnson & Johnson$2K
  • Boston Scientific$1K
  • Merck$1K
  • Novartis$905
  • E.r. Squibb & Sons, L.L.C.$861
  • plus $7K from 48 others

What the payments were for

  • Speaking & faculty fees$3502%
  • Food & beverage$15,50998%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,871 in reported general payments places this provider in the 80th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$248,123
Medicare patients
1,158
Services billed
2,742

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban402$446,499
XareltoRivaroxaban114$134,669
OzempicSemaglutide79$85,049
EntrestoSacubitril/Valsartan40$65,336
MounjaroTirzepatide35$48,702
JardianceEmpagliflozin26$38,010
Repatha SureclickEvolocumab24$23,651
LivaloPitavastatin Calcium12$9,646
Metoprolol Succinate526$8,022
BrilintaTicagrelor13$7,898
Atorvastatin Calcium546$7,771
EdarbiAzilsartan Medoxomil12$7,680
Nebivolol Hcl97$5,675
Rosuvastatin Calcium273$4,935
BystolicNebivolol Hcl22$3,908

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$449$446,499402 claims
Johnson & JohnsonXarelto$1,776$134,669114 claims
Novo NordiskOzempic$522$85,04979 claims
NovartisEntresto$905$65,33640 claims
Lilly USA, LLCMounjaro$33$48,70235 claims
Boehringer IngelheimJardiance$401$38,01026 claims
Kowa Pharmaceuticals America, Inc.Livalo, Bystolic$252$13,55434 claims
AstraZenecaBrilinta$206$7,89813 claims
Arbor Pharmaceuticals, Inc.Edarbi$102$7,68012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Teaneck

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →